The one dose vaccine from Johnson & Johnson has been categorised as “safe” and “effective in trials”, according to the U.S. Food and Drug Administration (FDA), in a report published today.
The panel of experts from the FDA will meet again on Friday February 26, to discuss if the vaccine can be approved for emergency use.
The vaccine is said to be “effective at preventing asymptomatic infections,” according to documents submitted to the FDA by Johnson & Johnson.
The documents also said that the vaccine had an 88% efficacy rate during a preliminary analysis of its trial.
Johnson &Johnson’s vaccine was 66% effective in preventing COVID-19 against multiple variants in a global trial involving nearly 44,000 people, according to Reuters.
The trial tested the efficacy of vaccine towards different populations, and found that it was 72% in the United States to 66% in Latin America and 57% in South Africa, with the new variant.
The trial also found that the vaccine was effective in reducing the risk of COVID-19 and preventing PCR-test confirmed COVID-19 at least 14 days after vaccination, according to the FDA’s report.
The report noted that three test subjects has severe side effects in the trial that were likely related to the vaccine, but the FDA concluded that the vaccine did not raise “any specific safety concerns” that would halt its authorisation for emergency use.
This comes after Taoiseach Micheal Martin said that more than 1m doses of the COVID-19 vaccine will be administered per month throughout May and June, meaning that 65% of the country should be fully vaccinated by the end of June.
The J&J vaccine could provide an alternative method of inoculation as the pharmaceutical company AstraZeneca is expected to deliver less than half the COVID-19 vaccines it was contracted to supply the European Union in the second quarter.